🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "major milestone" in the fight against increasingly resistant strains of the infection, according to health experts.

An International Public Health Issue

Gonorrhoea infections are on the rise around the world, with figures suggesting in excess of 82 million instances annually. Notably increased rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely advancement in the face of growing infection rates, increasing antimicrobial resistance and the extremely scarce available drugs currently available.”

Health officials are deeply concerned about the increase in drug-resistant strains. The global health body has designated it as a "priority pathogen". A tracking program revealed that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Gain Authorization

One new antibiotic, also known as Nuzolvence, was cleared by the US FDA in mid-December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers hope that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GSK, gained clearance in the same week. This drug, which is also used to treat UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This authorization signifies a significant shift in the treatment of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Testing Results and Global Access

According to results detailed in a major medical journal, zoliflodacin cured more than 90% of cases of the STI. This establishes an similar efficacy with the typical regimen, which involves a dual-drug approach. The study enrolled nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the rights to make available and distribute the drug in a wide range of developing nations.

Doctors treating patients have expressed hope. Having a one-pill regimen such as this is seen as a "revolutionary step" for public health efforts. This is considered vital to reduce the burden of the infection for patients and to prevent the spread of untreatable gonorrhoea around the world.